Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Study Identifier
M03-658
CT.gov Identifier
EudraCT Identifier
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete

Results Available

Scientific Result Summary
Available Language(s): English

Study Details

Medical Condition
  • Dermatology - Psoriasis (PsO)
  • Study Drug
  • adalimumab
  • Phase
    Phase 3
    Sex
    Female & Male
    Age
    18+ years

    Protocol Summary

    The two objectives of this study were to evaluate long-term efficacy and safety of adalimumab

    treatment in participants who had moderate to severe chronic plaque psoriasis and to evaluate

    the effectiveness of adalimumab retreatment in participants who had therapeutic response to

    adalimumab and were then withdrawn from adalimumab treatment.

    Study Locations

    Location
    Status
    Location
    Site Reference ID/Investigator# 1263
    Birmingham, Alabama, United States, 35205
    Status
    Not applicable
    Location
    Site Reference ID/Investigator# 1259
    Buckner 13075 PI, Alabama, United States, 35233
    Status
    Not applicable
    Location
    Site Reference ID/Investigator# 2427
    Scottsdale, Arizona, United States, 85251
    Status
    Not applicable
    Location
    Site Reference ID/Investigator# 2433
    Tucson, Arizona, United States, 85710
    Status
    Not applicable
    Location
    Site Reference ID/Investigator# 100
    Little Rock, Arkansas, United States, 72205
    Status
    Not applicable
    Location
    Site Reference ID/Investigator# 1798
    Bakersfield, California, United States, 93309
    Status
    Not applicable
    Showing {first} - {last} of {total} Results